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REPLY
We appreciate the interest by Dr. Rassi in our recent study on the
role of angiotensin-converting enzyme (ACE) inhibitors and
angiotensin receptor blockers (ARBs) in diabetes prevention (1).
We agree that lifestyle modifications that increase physical activity
and minimize abdominal obesity are the most rational and cost-
effective strategies for preventing type 2 diabetes. Despite this
knowledge, compliance with a prescription for daily exercise and
lasting weight loss proves difficult for many people; the epidemic of
diabetes continues to escalate. Thus, safe pharmacologic ap-
proaches for preventing this disease will probably be relevant and
important for many individuals.
Screening for new-onset diabetes using the American Diabetes
Association criteria of a fasting plasma glucose of 126 mg/dl at
two different visits in patients with no diabetes at the time of
enrollment is a valid initial test to identify this disease at its early
stages and prevent its chronic sequelae. However, the use of data
from relatively short-term studies to calculate a number-needed-
to-treat (NNT) can be misleading, as the risk of diabetes accrues
over decades or, indeed, a lifetime.
Insulin resistance is a common pathophysiologic disturbance
that plays a causal role in both hypertension and type 2 diabetes. It
also results in overactivity of the rennin-angiotensin-aldosterone
system leading to hypertrophy and stiffening of smooth muscles in
the arterial wall and left ventricle. Angiotensin-converting enzyme
inhibitors and ARBs have a proven efficacy for improving outcomes
in insulin-resistant conditions, such as hypertension, coronary heart
disease (CHD), and congestive heart failure, and they are the most
effective antihypertensive agents for regressing smooth muscle hyper-
trophy commonly seen in these conditions (2). The fact that they also
reduce the risk of new-onset diabetes is just one more reason to choose
them for these established indications over other antihypertensive
agents that worsen insulin sensitivity, such as traditional beta-blockers
and diuretics (3).
Metabolic syndrome is a more robust marker for risk of type 2
diabetes and CHD events (4). If the NNT with an ACE inhibitor
or ARB to prevent the development of new-onset diabetes in these
patients is to be calculated, it will be substantially lower than that
found in populations from our study, who were obviously at a
lower risk. Therefore, as we have advocated, targeting high-risk
prediabetic individuals for use of an ACE inhibitor or ARB
therapy will increase the cost-effectiveness of these medications.
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Long-Term Bosentan
Treatment in Children With
Pulmonary Arterial Hypertension
One of the core principles of scientific research is to provide full
details of the experimental methods for replication in further study
or clinical practice. As with many published studies (1), Rosenz-
weig et al. (2) failed to provide details of the drug formulation in
their report. Bosentan is currently only commercially available in
tablet form, and the dosing used in their study appears to be
multiples of halved/quartered tablets. It is widely recognized that
splitting tablets causes significant dosing inaccuracy, even when
commercially available tablet cutters are used (3,4). Furthermore,
many children are unable to swallow whole tablets (5), and
crushing the tablets can impair drug absorption (6). Rosenzweig
et al. (2) do not report how their patients took the dose (whether
or not it was swallowed whole).
If the published report does not detail the drug formulation and
method of administration, the reliability of any findings is ques-
tionable as the methods cannot be repeated accurately. If tablets
were cut in half/quartered and crushed, both the amount of drug
administered and its absorption are questionable, bringing the
validity of the results into doubt.
In their report, Rosenzweig et al. (2) cite a pharmacokinetic
study (7) on the dosing of bosentan in pediatric patients that also
fails to give formulation and administration details and whose
lowest dose is 31.25 mg as opposed to 15.6 mg in Rosenzweig et al.
(2). Bosentan may well be a useful agent in the treatment of
pulmonary arterial hypertension in children; surely it is now time
that a pediatric liquid formulation be developed, the efficacy and
dose optimization of which can be addressed in a well-conducted
prospective clinical trial.
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